PT - JOURNAL ARTICLE AU - Oluwaseyi Olulana AU - Vida Abedi AU - Venkatesh Avula AU - Durgesh Chaudhary AU - Ayesha Khan AU - Shima Shahjouei AU - Jiang Li AU - Ramin Zand TI - Regional Association of Disability and SARS-CoV-2 Infection in 369 Counties of the United States AID - 10.1101/2020.06.24.20139212 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.24.20139212 4099 - http://medrxiv.org/content/early/2020/06/26/2020.06.24.20139212.short 4100 - http://medrxiv.org/content/early/2020/06/26/2020.06.24.20139212.full AB - Background There have been outbreaks of SARS-CoV-2 in long term care facilities and recent reports of disproportionate death rates among the vulnerable population. The goal of this study was to better understand the impact of SARS-CoV-2 infection on the non-institutionalized disabled population in the United States using data from the most affected states as of April 9th, 2020.Methods This was an ecological study of county-level factors associated with the infection and mortality rate of SARS-CoV-2 in the non-institutionalized disabled population. We analyzed data from 369 counties from the most affected states (Michigan, New York, New Jersey, Pennsylvania, California, Louisiana, Massachusetts) in the United States using data available by April 9th, 2020. The variables include changes in mobility reported by Google, race/ethnicity, median income, education level, health insurance, and disability information from the United States Census Bureau. Bivariate regression analysis adjusted for state and median income was used to analyze the association between death rate and infection rate.Results The independent sample t-test of two groups (group 1: Death rate≥3.4% [median] and group 2: Death rate < 3.4%) indicates that counties with a higher total population, a lower percentage of Black males and females, higher median income, higher education, and lower percentage of disabled population have a lower rate (< 3.4%) of SARS-CoV-2 related mortality (all p-values<4.3E-02). The results of the bivariate regression when controlled for median income and state show counties with a higher White disabled population (est: 0.19, 95% CI: 0.01-0.37; p-value:3.7E-02), and higher population with independent living difficulty (est: 0.15, 95% CI: −0.01-0.30; p-value: 6.0E-02) have a higher rate of SARS-CoV-2 related mortality. Also, the regression analysis indicates that counties with higher White disabled population (est: - 0.22, 95% CI: −0.43-(-0.02); p-value: 3.3E-02), higher population with hearing disability (est: −0.26, 95% CI: - 0.42- (-0.11); p-value:1.2E-03), and higher population with disability in the 18-34 years age group (est: −0.25, 95% CI: −0.41-(-0.09); p-value:2.4E-03) show a lower rate of SARS-CoV-2 infection.Conclusion Our results indicate that while counties with a higher percentage of non-institutionalized disabled population, especially White disabled population, show a lower infection rate, they have a higher rate of SARS-CoV-2 related mortality.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is not a primary research article and this data was publicly available data from U.S census, Google and USAFactsFunding StatementSource of Funding: This study has no source of funding. RZ and VA have funding support from the Geisinger Health Plan Quality Fund as well as the National Institute of Health R56HL116832 (sub-award) during the study period. The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was needed for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that supports the findings of this school can be found on U.S Census, USAFacts and Google websites.